Effectiveness and Safety Evaluation of Chinese Medicine in Treatment of Metastatic Colorectal Cancer after Chemotherapy Failure: Protocol of a Prospective Multicenter Cohort Study

Teng-teng HAO; Yun XU; Ning CUI; Qian QU; Bi-yan LIANG; Ju-hua YUAN; Yang ZHAO; Qing-na LI; Fang LU; Yu WU

doi:10.1007/s11655-020-3420-0

Your Location：

Home >

Browse articles >

Effectiveness and Safety Evaluation of Chinese Medicine in Treatment of Metastatic Colorectal Cancer after Chemotherapy Failure: Protocol of a Prospective Multicenter Cohort Study

Original Article | Updated：2021-09-01

- Effectiveness and Safety Evaluation of Chinese Medicine in Treatment of Metastatic Colorectal Cancer after Chemotherapy Failure: Protocol of a Prospective Multicenter Cohort Study
- Chinese Journal of Integrative Medicine Vol. 27, Issue 9, Pages: 674-679(2021)
- Affiliations：
  
  1.Department of Oncology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing(100091), China
  2.Chinese Mdeicine Center for AIDS Prevention and Treatment, China Academy of Chinese Medical Sciences, Beijing(100700), China
  3.Department of Oncology, Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing(100039), China
  4.Institute of Clinical Pharmacology, Xiyuan Hospital, China Academy of Chinese Medicine Sciences, Beijing(100091), China
- Author bio：
  
  Prof. WU Yu, E-mail: wy713@vip.sina.com
- Funds：
- DOI：10.1007/s11655-020-3420-0
  CLC：
- Published：01 September 2021，
  
  Published Online：19 August 2020，
  
  Accepted：11 February 2020
Scan for full text
Teng-teng HAO, Yun XU, Ning CUI, et al. Effectiveness and Safety Evaluation of Chinese Medicine in Treatment of Metastatic Colorectal Cancer after Chemotherapy Failure: Protocol of a Prospective Multicenter Cohort Study. [J]. Chinese Journal of Integrative Medicine 27(9):674-679(2021)
DOI：

Teng-teng HAO, Yun XU, Ning CUI, et al. Effectiveness and Safety Evaluation of Chinese Medicine in Treatment of Metastatic Colorectal Cancer after Chemotherapy Failure: Protocol of a Prospective Multicenter Cohort Study. [J]. Chinese Journal of Integrative Medicine 27(9):674-679(2021) DOI： 10.1007/s11655-020-3420-0.

摘要

Abstract

Background:

Colorectal cancer (CRC) is the second most common cause of cancer-related deaths and has the third highest incidence in the world. Almost half of the patients with CRC have metastases at the time of diagnosis. However

the treatment for patients with metastatic CRC that progresses after approved conventional chemotherapy is still controversial. Chinese medicine (CM) has unique characteristics and advantages in treating metastatic CRC.

Objective:

To assess the effectiveness and safety of CM in patients with metastatic CRC after failure of conventional chemotherapy.

Methods:

The study is a multicenter prospective cohort study. A total of 384 patients with documented metastatic CRC after failure of conventional chemotherapy will be included from 9 hospitals at Beijing

Shanghai

Nanjing

and Guizhou

and assigned to three groups according to paitents' wishes: (1) integrated Chinese and Western medicine (ICM) group receiving CM herbal treatment combined with Western medicine (WM) anti-tumor therapy

(2) Chinese medicine (CM) group receiving only CM herbal treatment

and (3) WM group receiving only WM anti-tumor therapy. The primary endpoint is the overall survival (OS). Secondary endpoints include the progression free survival (PFS)

quality of life (QOL) assessed by the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) questionnaire

tumor control

and CM symptom score.

Discussion:

This prospective study will assess the effectiveness and safety of CM in treating metastatic CRC after conventional chemotherapy failure. Patients in the ICM group will be compared with those in the WM group and CM group. If certified to be effective

national provision of CM treatment in metastatic CRC will probably be advised. (Registration No. NCT02923622)

关键词

Keywords

colorectal cancerconventional chemotherapycomplementary therapyChinese medicineeffectiveness

references

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 2018;68:394-424.

Douaiher J, Ravipati A, Grams B, Chowdhury S, Alatise O, Are C. Colorectal cancer-global burden, trends, and geographical variations. J Surg Oncol 2017;115:619-630.

Lee WS, Yun SH, Chun HK, Lee WY, Yun HR, Kim J, et al.Pulmonary resection for metastases from colorectal cancer:prognostic factors and survival. Int J Colorectal Dis 2007;22:699-704.

Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007;14:766-770.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27:1386-1422.

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase Ⅲ trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin(FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer:the PRIME study. J Clin Oncol 2010;28:4697-4705.

Iwamoto S, Maeda H, Hazama S, Oba K, Okayama N, Suehiro Y, et al. Efficacy of CapeOX plus cetuximab treatment as a first-line therapy for patients with extended RAS/BRAF/PIK3CA wild-type advanced or metastatic colorectal cancer. J Cancer 2018;9:4092-4098.

Vogel A, Hofheinz RD, Kubicka S, Arnold D. Treatment decisions in metastatic colorectal cance—beyond first and second line combination therapies. Cancer Treat Rev 2017;59:54-60.

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 2018;29:44-70.

Hamilton SR, Aaltonen LA. Pathology and genetics of tumors of the digestive system. Health Organization classification of tumors. Lyon: IARCP; 2000.

NCCN clinical practice guidelines in oncology (NCCN Guidelines): colon cancer (2015.V3). Available at: http://guide.medlive.cn/guideline/8748http://guide.medlive.cn/guideline/8748.

NCCN clinical practice guidelines in oncology (NCCN Guidelines): rectal cancer (2015.V3). Available at: http://guide.medlive.cn/guideline/8745http://guide.medlive.cn/guideline/8745.

Ministry of Health of the People's Republic of China. Guiding principles of clinical research on new drugs of traditional Chinese medicine" (part Ⅱ). Beijing: Ministry of Health Press; 1995.

Yoo HJ, Kim JC, Eremenco S, Han OS. Quality of life in colorectal cancer patients with colectomy and the validation of the Functional Assessment of Cancer Therapy-Colorectal(FACT-C), version 4. J Pain Symptom Manage 2005;30:24-32.

Yu CL, Fielding R, Chan CL, Tse VK, Choi PH, Lau WH, et al.Measuring quality of life of Chinese cancer patients: a validation of the Chinese version of the Functional Assessment of Cancer Therapy-General (FACT-G) scale. Cancer 2000;88:1715-1727.

Liu YJ, Zhu GP, Guan XY. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiationinduced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol 2012;48:554-559.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nal Cancer Ins Monogr 2000;92:205-216.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.

Shu JH, Zhou RY, Zhong Y, Wu LY. Treatment of 45 cases of advanced colorectal cancer with "Yiqi Jiedu Decoction" and CapeOX chemotherapy. Shanghai J Tradit Chin Med (Chin)2011;5:33-35, 45.

Zhang YB, Liu X, Ji Q, Zhou LH, Sui H, Hou FG, et al. Clinical research on treating metastatic colorectal cancer with Jianpi Jiedu Decoction and chemotherapy. J Tradit Chin Med (Chin)2015;6:2090-2093.

McQuade JL, Meng Z, Chen Z, Wei Q, Zhang Y, Bei W, et al. Utilization of and attitudes towards traditional Chinese medicine therapies in a Chinese cancer hospital: a survey of patients and physicians. Evid Based Complement Alternat Med 2012;2012:504507.

Xu Y, Mao JJ, Sun L, Yang L, Li J, Hao Y, et al. Association between use of traditional Chinese medicine herbal therapy and survival outcomes in patients with stage Ⅱ and Ⅲ colorectal cancer: a multicenter prospective cohort study. J Natl Cancer Inst Monogr 2017:2017: lgx015.

Zhang T, He WT, Zi MJ, Song G, Yi DH, Yang YF. Cohort study on prognosis of patients with metastatic colorectal cancer treated with integrated Chinese and Western medicine. Chin J Integr Med 2018;24:573-578.

Kummar S, Copur MS, Rose M, Wadler S, Stephenson J, O'Rourke M, et al. A phase Ⅰ study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2011;10:85-96.

Zhang T, Yang YF, He B, Yi DH, Hao J, Zhang D. Efficacy and safety of Quxie Capsule in metastatic colorectal cancer: a double-blind randomized placebo controlled trial. Chin J Integr Med 2018;24:171-177.

Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet Oncol 2015;16:619-629.

Yamaguchi K, Komatsu Y, Satoh T, Uetake H, Yoshino T, Nishida T, et al. Large-scale, prospective observational study of regorafenib in Japanese patients with metastatic colorectal cancer in a real-world clinical setting. Oncologist 2019, 24:2018-0377.

Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, et al.Results of a randomized, double-blind, placebo-controlled, phase iii trial of trifluridine/tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol 2018;36:350-358.

Chu JN, Choi J, Ostvar S, Torchia JA, Reynolds KL, Tramontano A, et al. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Cancer 2019;125:278-289.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Patrinia scabiosaefolia Inhibits Growth of 5-FU-Resistant Colorectal Carcinoma Cells via Induction of Apoptosis and Suppression of AKT Pathway

Effectiveness of Integrative Medicine Therapy on Coronary Artery Disease Prognosis: A Real-World Study

Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini

Immunomodulatory Function of Pien Tze Huang in T Cell-Mediated Anti-tumor Activity against B16-F10, MC38 and Hep1-6 Tumor Models

Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

Related Author

No data

Related Institution

College of Pharmacy, Fujian University of Traditional Chinese Medicine

Fujian Key Laboratory of Integrative Medicine on Geriatric, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine

Department of Cardiology, Beijing Anzhen Hospital Affiliated to Capital Medical University—Beijing Institute of Heart, Lung and Blood Vessel Diseases

Center for Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences

Department of Cardiology, Beijing Chinese Medicine Hospital Affiliated to Capital Medical University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰